These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 32619431)

  • 1. Measuring of IgG2c isotype instead of IgG2a in immunized C57BL/6 mice with Plasmodium vivax TRAP as a subunit vaccine candidate in order to correct interpretation of Th1 versus Th2 immune response.
    Nazeri S; Zakeri S; Mehrizi AA; Sardari S; Djadid ND
    Exp Parasitol; 2020 Sep; 216():107944. PubMed ID: 32619431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccine adjuvants CpG (oligodeoxynucleotides ODNs), MPL (3-O-deacylated monophosphoryl lipid A) and naloxone-enhanced Th1 immune response to the Plasmodium vivax recombinant thrombospondin-related adhesive protein (TRAP) in mice.
    Nazeri S; Zakeri S; Mehrizi AA; Djadid ND; Snounou G; Andolina C; Nosten F
    Med Microbiol Immunol; 2018 Nov; 207(5-6):271-286. PubMed ID: 29948091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunological evaluation of two novel engineered Plasmodium vivax circumsporozoite proteins formulated with different human-compatible vaccine adjuvants in C57BL/6 mice.
    Shabani SH; Zakeri S; Mortazavi Y; Mehrizi AA
    Med Microbiol Immunol; 2019 Dec; 208(6):731-745. PubMed ID: 31025102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of immune responses to a Plasmodium vivax CSP-based recombinant protein vaccine candidate in combination with second-generation adjuvants in mice.
    Lumsden JM; Nurmukhambetova S; Klein JH; Sattabongkot J; Bennett JW; Bertholet S; Fox CB; Reed SG; Ockenhouse CF; Howard RF; Polhemus ME; Yadava A
    Vaccine; 2012 May; 30(22):3311-9. PubMed ID: 22425788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Th1 immune response to Plasmodium falciparum recombinant thrombospondin-related adhesive protein (TRAP) antigen is enhanced by TLR3-specific adjuvant, poly(I:C) in BALB/c mice.
    Mehrizi AA; Ameri Torzani M; Zakeri S; Jafary Zadeh A; Babaeekhou L
    Parasite Immunol; 2018 Jul; 40(7):e12538. PubMed ID: 29799636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of three recombinant multi-antigenic vaccines composed of surface and secretory antigens of Toxoplasma gondii in murine models of experimental toxoplasmosis.
    Dziadek B; Gatkowska J; Brzostek A; Dziadek J; Dzitko K; Grzybowski M; Dlugonska H
    Vaccine; 2011 Jan; 29(4):821-30. PubMed ID: 21087690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Naturally acquired immune responses to thrombospondin-related adhesion protein (TRAP) of Plasmodium vivax in patients from areas of unstable malaria transmission.
    Nazeri S; Zakeri S; Mehrizi AA; Djadid ND
    Acta Trop; 2017 Sep; 173():45-54. PubMed ID: 28549910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Poly(I:C) adjuvant strongly enhances parasite-inhibitory antibodies and Th1 response against Plasmodium falciparum merozoite surface protein-1 (42-kDa fragment) in BALB/c mice.
    Mehrizi AA; Rezvani N; Zakeri S; Gholami A; Babaeekhou L
    Med Microbiol Immunol; 2018 Apr; 207(2):151-166. PubMed ID: 29397427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody Responses Against
    Matos ADS; Rodrigues-da-Silva RN; Soares IF; Baptista BO; de Souza RM; Bitencourt-Chaves L; Totino PRR; Sánchez-Arcila JC; Daniel-Ribeiro CT; López-Camacho C; Reyes-Sandoval A; Pratt-Riccio LR; Lima-Junior JDC
    Front Immunol; 2019; 10():2230. PubMed ID: 31620136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity of Plasmodium vivax merozoite surface protein-9 recombinant proteins expressed in E. coli.
    Oliveira-Ferreira J; Vargas-Serrato E; Barnwell JW; Moreno A; Galinski MR
    Vaccine; 2004 May; 22(15-16):2023-30. PubMed ID: 15121316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The hepatitis B virus core and e antigens elicit different Th cell subsets: antigen structure can affect Th cell phenotype.
    Milich DR; Schödel F; Hughes JL; Jones JE; Peterson DL
    J Virol; 1997 Mar; 71(3):2192-201. PubMed ID: 9032353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 18β-glycyrrhetinic acid induces immunological adjuvant activity of Th1 against Candida albicans surface mannan extract.
    Kim J; Joo I; Kim H; Han Y
    Phytomedicine; 2013 Aug; 20(11):951-5. PubMed ID: 23746951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity of Plasmodium falciparum and Plasmodium vivax circumsporozoite protein repeat multiple antigen constructs (MAC).
    Udhayakumar V; Saekhou A; Fang S; Jue D; Wohlhueter RM; Lal AA
    Vaccine; 1998; 16(9-10):982-8. PubMed ID: 9682348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of adjuvants on murine immune responses against the C-terminal 19 kDa fragment of Plasmodium vivax merozoite surface protein-1 (MSP-1).
    Yang C; Collins WE; Xiao L; Patterson PS; Reed RC; Hunter RL; Kaslow DC; Lal AA
    Parasite Immunol; 1996 Nov; 18(11):547-58. PubMed ID: 9226693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-lasting humoral and cellular immune responses elicited by immunization with recombinant chimeras of the Plasmodium vivax circumsporozoite protein.
    Almeida AP; Dias MO; Vieira Cde A; Chávez-Olórtegui C; Gazzineli RT; Rodrigues MM; Fujiwara RT; Bruna-Romero O
    Vaccine; 2014 Apr; 32(19):2181-7. PubMed ID: 24582631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trypanosoma cruzi: protective immunity in mice immunized with paraflagellar rod proteins is associated with a T-helper type 1 response.
    Miller MJ; Wrightsman RA; Manning JE
    Exp Parasitol; 1996 Nov; 84(2):156-67. PubMed ID: 8932765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Synthetic Nanoparticle Based Vaccine Approach Targeting MSP4/5 Is Immunogenic and Induces Moderate Protection Against Murine Blood-Stage Malaria.
    Wilson KL; Pouniotis D; Hanley J; Xiang SD; Ma C; Coppel RL; Plebanski M
    Front Immunol; 2019; 10():331. PubMed ID: 30930890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New malaria vaccine candidates based on the Plasmodium vivax Merozoite Surface Protein-1 and the TLR-5 agonist Salmonella Typhimurium FliC flagellin.
    Bargieri DY; Rosa DS; Braga CJ; Carvalho BO; Costa FT; Espíndola NM; Vaz AJ; Soares IS; Ferreira LC; Rodrigues MM
    Vaccine; 2008 Nov; 26(48):6132-42. PubMed ID: 18804504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell-traversal protein for ookinetes and sporozoites (CelTOS) formulated with potent TLR adjuvants induces high-affinity antibodies that inhibit Plasmodium falciparum infection in Anopheles stephensi.
    Pirahmadi S; Zakeri S; A Mehrizi A; D Djadid N; Raz AA; J Sani J; Abbasi R; Ghorbanzadeh Z
    Malar J; 2019 Apr; 18(1):146. PubMed ID: 31014347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus.
    Fotouhi F; Shaffifar M; Farahmand B; Shirian S; Saeidi M; Tabarraei A; Gorji A; Ghaemi A
    Arch Virol; 2017 May; 162(5):1251-1260. PubMed ID: 28120096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.